

### REMARKS

In response to the Notice to comply with Sequence Requirements, dated 3 July 2006, Applicants have deleted the previous sequence listing and replaced it with the corrected paper sequence listing accompanying this response. An identical sequence listing is also submitted in computer readable form on 3.5" diskette.

Applicants have inserted the current application serial number and filing date, have corrected the formatting for the identifiers at SEQ ID NO: 25, have removed the spurious "<" symbol at <213> of SEQ ID NO: 27 and have corrected the feature line <223> for each of SEQ ID NO: 31 through 54 to indicate that the fragment is a fragment of the human HFE2A gene (which is supported in the filed application at page 54, lines 22-28, and at page 19, lines 6-11, and Table 3).

Applicant believes that no fee is due in making this response. If any fee is due, the Commission is authorized to charge any additional fees, or credit any overpayment, to Deposit Acct. No. 03-0678.



Serial No.: 10/552,158  
Docket No. 760050-154

**EXPRESS MAIL CERTIFICATE**

Express Mail Label No. EV439772995US

Deposit Date: 3 August 2006

I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above addressed to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

Alan J. Grant, Esq.

8/3/06

Date

Respectfully submitted,

Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
5 Becker Farm Road  
Roseland, NJ 07068  
Tel. No.: (973) 994-1700